The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     
 


The Journal of Immunology, 2007, 179: 7365-7375.
Copyright © 2007 by The American Association of Immunologists, Inc.

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Zhou, P.
Right arrow Articles by Schebye, X. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Zhou, P.
Right arrow Articles by Schebye, X. M.

Pivotal Roles of CD4+ Effector T cells in Mediating Agonistic Anti-GITR mAb-Induced-Immune Activation and Tumor Immunity in CT26 Tumors

Pengfei Zhou, Lawrence L’italien, Douglas Hodges and Xiao Min Schebye1

Discovery Research, Schering-Plough Biopharma (Formerly DNAX Research Institute), Palo Alto, CA 94304-1104

Glucocorticoid-induced TNF receptor family related protein (GITR) is a member of the TNFR superfamily. Previous studies have shown that in vivo administration of a GITR agonistic Ab (DTA-1) is able to overcome tolerance and induce tumor rejection in several murine syngeneic tumor models. However, little is known about the in vivo targets and the mechanisms of how this tolerance is overcome in a tumor-bearing host, nor is much known about how the immune network is regulated to achieve this antitumor response. In this study, we demonstrate that the in vivo ligation of GITR on CD4+ effector T cells renders them refractory to suppression by regulatory T (Treg) cells in the CT26 tumor-bearing mouse. GITR engagement on Treg cells does not appear to directly abrogate their suppressive function; rather, it increases the expansion of Treg cells and promotes IL-10 production, a cytokine important for their suppressive function. Moreover, CD4+ effector T cells play a crucial role in mediating DTA-1-induced immune activation and expansion of CD8+, NK, and B cells in the tumor-draining lymph nodes. This includes increased CD69 expression on all of these subsets. In addition, NK and tumor-specific CD8+ T cells are generated that are cytolytic, which show increased intracellular IFN-{gamma} production and CD107a mobilization, the latter a hallmark of cytolytic activities that lead to tumor killing.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

1 Address correspondence and reprint requests to Dr. Xiao Min Schebye, Schering-Plough Biopharma, 901 California Avenue, Palo Alto, CA 94304. E-mail address: xiaomin.schebye{at}spcorp.com

2 Abbreviations used in this paper: Treg, regulatory T cell; GITR, glucocorticoid-induced TNF receptor family related gene; TDLN, tumor draining lymph node.







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Website Copyright © 2007 by The American Association of Immunologists, Inc. All rights reserved.
All Contents Copyright © 2007 by The American Association of Immunologists, Inc. All rights reserved.